Novartis AG Drug SigniforR Gets EU Approval as the First Medication to Treat Patients With Cushing’s Disease

Basel, April 25, 2012 - Novartis announced today that the European Commission has approved SigniforR (pasireotide) for the treatment of adult patients with Cushing's disease for whom surgery is not a…
Read the full story: BioSpace.com Featured News